Saisei Pharma is a bio venture company established at Tokushima university in 2014, developing Oral Colostrum GcMAF and researching ultrasonic sensitizers and electric field therapy. And it aims to treat acute infection, chronic infection, cancer, autism, chronic fatigue syndrome, multiple sclerosis, rheumatoid arthritis, Alzheimer’s disease, dementia and many other diseases.
Colostrum is a form of milk produced by the mammary glands the first few days after giving birth before true milk appears. Colostrum contains antibodies to protect the newborn against bacteria, viruses and various kinds of diseases.
Cow colostrum contains immunoglobulin such as IgG, IgA and IgM. And it is also high in lactoferrin, growth factor, mineral and vitamin.
The research on cow colostrum has been proceeding. Here are some reports about the effectiveness on the human body.
Immune system is a system to keep your body healthy. It protects you from bacteria and viruses, and also it can get rid of cancer cells. However, the biological function and physical performance reach their peak from the 20s of age, waning in half in the 40s. As the immune system weakens with age, it becomes easier to get sick. So it is important to keep boosting your immune system and keep it young so that you can lead a good long life.
Macrophages function as NK cells which engulfs and digests cancer cells, viruses and microbes. It is produced by the differentiation of monocytes in tissue which account for 5 percentage in the white blood cells. This is an amoeboid cell and plays an important role in engulfing and digesting cellular debris, foreign substances, microbes and cancer cells. It used to be thought that there were two kinds of differentiations; macrophages that encourage inflammation called M1 macrophages and macrophages that decrease and encourage tissue repair called M2 macrophages.
But recently it has been believed that there are several activated forms of macrophages such as classic activated macrophages, wound healing macrophages, suppression macrophages or intermediate activated forms of macrophages. So the diversity of the macrophages’ activation still remains unknown.
There are several case reports of having treated HIV, breast cancer, colon cancer and prostate cancer by the activated macrophages. So the evaluation and recognition about the activated macrophages have started to be the focus of attention in treating many kinds of diseases.
This is the process of how the activated macrophages destroy the cancer cells.
Once the macrophages take in the antigen, it releases cytokines and activates a specific T cell. It fragments foreign substances that the macrophages have taken in and decomposed, and combines them with MHC-Ⅱ in the cells and presents them on the surface of the cell. This is called antigen presentation by the macrophages.
▲the macrophages are destroying the cancer cells
According to the animal experiments, it is identified that GcMAF has antiangiogenic effect of the cancer.
The signal of the antigen presentation by the macrophages is transmitted into a lymphocyte called T helper cells. Mature T helper cells express the surface protein CD4 and the receptor protein T-cell receptor. And each protein combines with MHC-Ⅱ of the macrophages and the antigen presented by the macrophages so that the macrophages start to be activated. The structure of the T-cell receptor is different depending on each T helper cell. Only a T helper cell which fits with an antigen fragment presented by the macrophages will be activated.
The activated T helper cells activate the macrophages by producing the cytokines such as interleukin and lymphokine as well as activate B cells which recognize the same antigen. The activated B cells differentiate into the antibody producing cells and increase, and then produce the antibody against the antigen, and then release them. And the antibody combines specifically with the antigen, and then engulfs the complex. The virus and microbes can be engulfed efficiently for the macrophages. Meanwhile T cells help activating macrophages, increasing and differentiating B cells by releasing lymphokine. Therefore, the macrophage activating treatment is a treatment that makes the most of the immune system that each person originally has. Furthermore, it can be said that this is the treatment which combines both NK cell treatment and Dendritic cell treatment.
These are the photos of Dr Yamamoto, who developed first generation GcMAF, and Dr Hitoshi Hori and Dr Yoshihiro Uto from Tokushima University, the center of the GcMAF development in Japan for the last 20 years.
|1991||Dr.Yamamoto discovered GcMAF.|
|1992||Dr.Yamamoto visited Tokushima university.|
|1998||Dr.Uto joined the development team.|
|2002||The first research paper was published.(The first generation GcMaf)|
|2010||Tokushima University and Saisei Mirai started to do research and develop the second generation GcMaf together.|
|2011||The second generation GcMaf was produced at Saisei Mirai Cell Culture Center as clinical trial, and the clinical validation was started.|
|2012||It's been 20 years since the GcMaf research started at Tokushima University.|
|2013||Over 1000 cases of the second generation GcMaf use were applied at Saisei Mirai.|
|2014||The third paper was published on Anticancer Research.|
|2015||Tokushima university and Saisei Mirai succeeded in the development of Colostrum GcMAF for the first time in the world.|
There are three genotypes such as Gc1f, Gc1s and Gc2 in Gc Subtype. There become six types in total because two dimers as homo and hetero are combined as phenotype. That is Gc1f1f, G1s1s, Gc22, Gc1f1s, Gc1f2 and Gc1s2.
GcProtein is transformed into GcMaf in response to sugar chain cut of activated β-galactosidase from activated B cells and Sialidase from T cells.
There are six important activities: acceleration of phagocytic activation, increase in superoxide production, inhibition of vascularization, promotion of the anti-tumor activity and dendritic cell maturation promotion. Increase of mononuclear number in blood and dendritic cell maturation promotion have not been reported. The slides below show these cases.
This is the tests used by mice. The group treated with the first generation GcMAF shows the strong tumor inhibitory effect compared to the one not treated. The tumor didn't get big.
This is also the tests used by mice. The black line shows the group not treated, and the green dot line shows the one treated with the first generation GcMAF. It clearly shows that the survival rate got prolonged compared to the one without treating and the one treated with the first generation GcMAF.
|TP||g/dl||6.5 - 8.2||6.5||4.5||4.1||6.2||5.8||6.2|
|Alb||g/dl||3.7 - 5.5||2||1.4||0.6||3.8||3.7||4|
|A/G||1.55 - 2.55||0.44||0.45||0.17||1.64||1.97||1.96|
|Alb||%||60.8 - 71.8||62.1||66.3||66.2|
|Uric acid (UA)||mg/dl||0||0||0.3|
|alpha1||%||1.7 - 2.9||3||3.6||3.4|
|alpha2||%||5.7 - 9.5||9.3||9.1||7.4|
|beta||%||7.2 - 11.1||8.9||8.5||10.2|
|gamma||%||10.2 - 20.4||16.7||12.5||12.8|
|IgG||mg/dl||820 - 1740||871||456||924||1139||907||1019|
|IgA||mg/dl||90 - 400||42||36||132||281||171||97|
|IgM||mg/dl||31 - 200||27||21||259||115||136||62|
They are similar. The first few hour colostrum after giving birth is particularly similar to serum. It is said that red colored milk is produced at first after a cow gave a birth. But after 24 hours, the component has been changed a lot and it becomes regular milk.
Peyer’s patch where there are plenty of macrophages
GALT, or Gut associated lymphoid tissue, is said to be the biggest macrophage pool in the body. And it is known that plenty of macrophages exist in the Peyer’s patch. Colostrum MAF aims to activate these macrophages directly. Professor Uto, Tokushima University, has started the basic experiment of colostrum MAF and GALT. And we are looking forward to the results.
It shows that 10ng first generation GcMAF and 100ng Colostrum MAF are almost the same in activation.
It shows that 100ng Oral Colostrum MAF and 10ng first generation GcMAF is almost the same in activation. Therefore, it is expected that using 10 times as much colostrum MAF will bring the same effect as the first generation GcMAF. Oral Colostrum MAF contains 200ng per capsule. So if one capsule a day is taken, it is expected to gain the same effect as the first generation GcMAF. But it is still under investigation. It should be possible to contain 1500ng per capsule.
By stimulating directly the lymphatic system near the lesioned part, the macrophages will be activated.
Taking sublingually, by nebulizer, by capsule, or by suppository are considered. It is thought that it should be more effective to stimulate directly the lymphatic system near the lesioned part. A clinic in Switzerland has been using the ultrasonic nebulizer to take GcMAF produced by the serum. But then we think that it will be needed to experiment to make sure if the structure of the GcMAF will not be changed by the ultrasonic nebulizer.
This is made into capsules and packaged.
Macrophage phagocytic activity is being tested. This test is the most important test to see the function of the macrophages.
Cancers, autism, chronic fatigue syndrome (CFS), lyme disease, infectious diseases such as influenza, Noro virus, malaria, dengue fever, HIV, hepatitis B type and C type, tuberculosis, autoimmune disease etc
Boeki Center Building
5-1-14 Hamabetori Chuo-ku
FAX: +81 (0)6-6902-7133
Nature 21 Building
TEL: +81 (0)6-6902-1001
ORE Hiroo Building
ORE Hiroo Building
Nature 21 Building